Condition 101 About Ganglioneuroblastoma

What is the definition of Ganglioneuroblastoma?

Ganglioneuroblastoma is an intermediate tumor that arises from nerve tissues. An intermediate tumor is one that is between benign (slow-growing and unlikely to spread) and malignant (fast-growing, aggressive, and likely to spread).

What are the causes for Ganglioneuroblastoma?

Ganglioneuroblastoma mostly occurs in children ages 2 to 4 years. The tumor affects boys and girls equally. It occurs rarely in adults. Tumors of the nervous system have different degrees of differentiation. This is based on how the tumor cells look under the microscope. It can predict whether or not they are likely to spread.

Benign tumors are less likely to spread. Malignant tumors are aggressive, grow quickly, and often spread. A ganglioneuroma is less malignant in nature. A neuroblastoma (occurring in children over 1 year old) is usually malignant.

A ganglioneuroblastoma may be only in one area or it may be widespread, but it is usually less aggressive than a neuroblastoma. The cause is unknown.

What are the symptoms for Ganglioneuroblastoma?

Most commonly, a lump can be felt in the abdomen with tenderness.

This tumor may also occur at other sites, including:

  • Chest cavity
  • Neck
  • Legs

What are the current treatments for Ganglioneuroblastoma?

Depending on the type of tumor, treatment can involve surgery, and possibly chemotherapy and radiation therapy.

Because these tumors are rare, they should be treated in a specialized center by experts who have experience with them.

What are the support groups for Ganglioneuroblastoma?

Organizations that provide support and additional information:

  • Children's Oncology Group -- www.childrensoncologygroup.org
  • The Neuroblastoma Children's Cancer Society -- www.neuroblastomacancer.org

What is the outlook (prognosis) for Ganglioneuroblastoma?

The outlook depends on how far the tumor has spread, and whether some areas of the tumor contain more aggressive cancer cells.

What are the possible complications for Ganglioneuroblastoma?

Complications that may result include:

  • Complications of surgery, radiation, or chemotherapy
  • Spread of the tumor into surrounding areas

When should I contact a medical professional for Ganglioneuroblastoma?

Call your provider if you feel a lump or growth on your child's body. Make sure children receive routine examinations as part of their well-child care.

REFERENCES

Harrison DJ, Ater JL. Neuroblastoma. In: Kliegman RM, St Geme JW, Blum NJ, Shah SS, Tasker RC, Wilson KM, eds. Nelson Textbook of Pediatrics. 21st ed. Philadelphia, PA: Elsevier; 2020:chap 525.

Myers JL. Mediastinum. In: Goldblum JR, Lamps LW, McKenney JK, Myers JL, eds. Rosai and Ackerman's Surgical Pathology. 11th ed. Philadelphia, PA: Elsevier; 2018:chap 12.

Latest Advances On Ganglioneuroblastoma

  • Condition: Adrenal Tumors in Children
  • Journal: BMC urology
  • Treatment Used: Robotic Adrenalectomy
  • Number of Patients: 3
  • Published —
In this study, researchers evaluated the outcomes of using robotic surgery for the treatment of adrenal tumors in children.
  • Condition: Central Nervous System Ganglioneuroblastoma with MYO5A-NTRK3 Fusion
  • Journal: Brain tumor pathology
  • Treatment Used: Gross Total Resection with Radiotherapy
  • Number of Patients: 1
  • Published —
This case report describes a patient with central nervous system ganglioneuroblastoma with a MYO5A-NTRK3 fusion that was treated using a gross total resection and radiotherapy.

Clinical Trials For Ganglioneuroblastoma

Clinical Trial
  • Status: Recruiting
  • Phase: Phase 2
  • Intervention Type: Drug, Biological
  • Participants: 40
  • Start Date: November 30, 2020
A Pilot Study of Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide in the Post-Consolidation Setting for High-Risk Neuroblastoma
Clinical Trial
  • Status: Recruiting
  • Phase: Early Phase 1
  • Intervention Type: Drug, Procedure
  • Participants: 20
  • Start Date: September 23, 2019
Utility of Gallium-68-DOTA-Octreotate PET/CT in the Characterization of Pediatric Neuroendocrine Tumors